Ketoconazole — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Dermatophyte Infections (Tinea/Ringworm)

• Clotrimazole
• Terbinafine
• Clotrimazole 1% cream
• Terbinafine 250 mg tabs

Also listed for Seborrheic Dermatitis

• Hydrocortisone
• Hydrocortisone 2.5% cream

Also listed for Tinea Versicolor

• Selenium Sulfide
• Selenium sulfide 2.5% lotion

Other medications in Infections

• Lamivudine
• Ledipasvir
• Linezolid
• Loracarbef
• Meropenem
• Minocycline
• Moxifloxacin
• Ofloxacin

What Ketoconazole is approved for (FDA label)

Ketoconazole tablets are not indicated for treatment of onychomycosis, cutaneous dermatophyte infections, or Candida infections. Ketoconazole tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks. Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebrospinal fluid.

Source: Read the full FDA label on DailyMed. Label effective date: August 10, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Ketoconazole (FDA label)

WARNING Because ketoconazole tablets have been associated with serious adverse reactions (see WARNINGS section), ketoconazole tablets are not indicated for treatment of onychomycosis, cutaneous dermatophyte infections, or Candida infections. Ketoconazole tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks. Hepatotoxicity Serious hepatotoxicity, including cases with a fatal outcome or requiring liver transplantation has occurred with the use of oral ketoconazole. Some patients had no obvious risk factors for liver disease. Patients receiving this drug should be informed by the physician of the risk and should be closely monitored. See WARNINGS section. QT Prolongation and Drug Interactions Leading to QT Prolongation Co-administration of the following drugs with ketoconazole is contraindicated: dofetilide, quinidine, pimozide, lurasidone, cisapride, methadone, disopyramide, dronedarone, ranolazine. Ketoconazole can cause elevated plasma concentrations of these drugs and may prolong QT intervals, sometimes resulting in life-threatening ventricular dysrhythmias such as torsades de pointes. See CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS: DRUG INTERACTIONS sections.

Source: FDA prescribing information (DailyMed). Set ID: 1d598696-c6f3-4b7c-ad73-949d2089df35. SPL document ID: 58b7a33f-9abe-2bcb-e063-6394a90ae4f1. Label effective date: August 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ketoconazole (FDA label)

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 1d598696-c6f3-4b7c-ad73-949d2089df35. SPL document ID: 58b7a33f-9abe-2bcb-e063-6394a90ae4f1. Label effective date: August 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ketoconazole (FDA label)

Drug Interactions Coadministration of a number of CYP3A4 substrates such as dofetilide, quinidine cisapride and pimozide is contraindicated with ketoconazole tablets. Coadministration with ketoconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both therapeutic and adverse effects to such an extent that a potentially serious adverse reaction may occur. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and sometimes resulting in life-threatening ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia. (See PRECAUTIONS: DRUG INTERACTIONS .) Coadministration of ketoconazole tablets with lurasidone is contraindicated since it may result in an increase in lurasidone exposure and the potential for serious adverse reactions (see PRECAUTIONS: DRUG INTERACTIONS ).

Source: FDA prescribing information (DailyMed). Set ID: 1d598696-c6f3-4b7c-ad73-949d2089df35. SPL document ID: 58b7a33f-9abe-2bcb-e063-6394a90ae4f1. Label effective date: August 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ketoconazole (FDA label)

Coadministration of a number of CYP3A4 substrates such as dofetilide, quinidine cisapride and pimozide is contraindicated with ketoconazole tablets. Coadministration with ketoconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both therapeutic and adverse effects to such an extent that a potentially serious adverse reaction may occur. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and sometimes resulting in life-threatening ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia. (See PRECAUTIONS: DRUG INTERACTIONS .) Coadministration of ketoconazole tablets with lurasidone is contraindicated since it may result in an increase in lurasidone exposure and the potential for serious adverse reactions (see PRECAUTIONS: DRUG INTERACTIONS ).

Source: FDA prescribing information (DailyMed). Set ID: 1d598696-c6f3-4b7c-ad73-949d2089df35. SPL document ID: 58b7a33f-9abe-2bcb-e063-6394a90ae4f1. Label effective date: August 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.